Porous cellulose microparticles and their use in, inter alias, cosmetic and pharmaceutic preparations are provided. These microparticles comprise cellulose I nanocrystals aggregated together, thus forming the microparticles, and arranged around cavities in the microparticles, thus defining pores in the microparticles. A method of for producing these microparticles is also provided. It involves mixing a suspension of cellulose I nanocrystals with an emulsion of a porogen to produce a mixture comprising a continuous liquid phase in which droplets of the porogen are dispersed and in which the nanocrystals of cellulose I are suspended; spray-drying the mixture to produce microparticles; and if the porogen has not sufficiently evaporated during spray-drying to form pores in the microparticles, evaporating the porogen or leaching the porogen out of the microparticles to form pores in the microparticles.

A reversible enrichment material, its preparation and application thereof are provided. The reversible enrichment material includes an inorganic carrier; and an active metal salt, a first metal salt promoter and a second metal salt promoter supported on the inorganic carrier. The active metal salt is a soluble silver salt, a soluble copper salt, or a combination thereof. The first metal salt promoter is one or more selected from the group consisting of soluble salts of Group IA, Group IIA and Group IIIA metals, and the second metal salt promoter is one or more selected from the group consisting of soluble salts of transition metals other than Group IB metals. The reversible enrichment material can realize effective separation of saturated hydrocarbon from unsaturated hydrocarbon and has good reversibility.

A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.

The present invention provides that powder is mainly constituted from secondary particles of hydroxyapatite. The secondary particles are obtained by drying a slurry containing primary particles of hydroxyapatite and aggregates thereof and granulating the primary particles and the aggregates. A bulk density of the powder is 0.65 g/mL or more and a specific surface area of the secondary particles is 70 m.sup.2/g or more. The powder of the present invention has high strength and is capable of exhibiting superior adsorption capability when it is used for an adsorbent an adsorption apparatus has.

Porous zirconia particles exhibit high specificity to a protein to be immobilized thereto and are used in immobilization of the protein. The porous zirconia particles have a pore diameter D50, at which a ratio of a cumulative pore volume to a total pore volume is 50%, the pore diameter D50 being in a range of 3.20 nm or more and 6.50 nm or less; and a pore diameter D90, at which a ratio of a cumulative pore volume to a total pore volume is 90%, the pore diameter D90 being in a range of 10.50 nm or more and 100.00 nm or less. The total pore volume of the particles is greater than 0.10 cm.sup.3/g. D50, D90, and the total pore volume are determined based on a pore diameter distribution measured through a BET method.

Disclosed herein is a method for obtaining compounds and compositions from plant and fungus materials by thermal treatment, affinity capture, filtration, and release through multi-phasic transitions between gas, solid, and liquid states. The compounds of interest are obtained by manipulating the temperature and pressure of the heating chamber. The compounds in gas phase are passed through an affinity medium which captures the compounds of interest in either solid or liquid phase by exposing the compound of interest to the localized micro-affinity environment of the medium. The compounds are separated from the medium using direct competition with solvent or buffers optimized for the specific chemical properties of compounds.

The present disclosure is directed to stationary phase materials for performing size exclusion chromatography. Embodiments of the present disclosure feature hydroxy-terminated polyethylene glycol surface modified silica particle stationary phase materials, which are optionally also methoxy-terminated polyethylene glycol surface modified.

The present disclosure is directed to stationary phase materials (e.g., porous inorganic-organic hybrid particles) for performing size exclusion chromatography. Embodiments of the present disclosure feature hydroxy-terminated polyethylene glycol surface modified stationary phase materials.

The present disclosure is directed to methods for performing size exclusion chromatography. Embodiments of the present disclosure feature methods for improving separations of proteinaceous analytes in size exclusion chromatography, for example, by using low concentrations of amino acids or derivatives thereof in the mobile phase.

An extracorporeal blood circulation device is provided with: a blood component adjuster; a blood purification device; a pipe system provided with a pump for supplying blood from a blood collecting part to the blood component adjuster, a valve for supplying a physiological saline solution, and a pressure gauge for sensing a pressure loss; a bypass pipe system for bypassing the blood component adjuster and supplying blood to the blood purification device; a pipe system for connecting the blood component adjuster and the blood purification device, the pipe system being provided with a pressure gauge for sensing a pressure loss; a pipe system provided with a valve for returning blood from the blood purification device to a reinfusion part and recovering the physiological saline solution, and a pressure gauge for sensing a pressure loss; and a control unit for switching to the bypass pipe system and switching to a reinfusion mode.